Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses using USB microscopes for scalp photos and provides a link to an overview of trichoscopy. Treatments mentioned include Minoxidil, finasteride, and RU58841.

A 33-year-old male is documenting his hair regrowth progress using minoxidil, red light therapy, copper peptides, and micro-needling, with noticeable improvement in hair thickness and coverage. He plans to add a topical finasteride/minoxidil spray and aims for a shadow on his scalp rather than a full head of hair.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.

A 40+ male shared his one-year progress using minoxidil twice daily and microneedling once a week, showing significant hair improvement. He also occasionally uses finasteride in a low dosage due to side effects.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841, and highlights hair multiplication research from Koehler Lab at Harvard. Users express optimism about future advancements.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

A user developed AI software to simulate hair transplants on photos, helping people visualize potential results. The tool offers photo-realistic renderings but advises caution regarding exact outcomes due to various factors.

The user has been using minoxidil, finasteride, and microneedling for two years, resulting in significant hair regrowth and plans for a 4000 graft hair transplant. The treatments have strengthened the donor area, making a hair transplant feasible.

Microneedling at 0.6mm depth every two weeks showed better hair growth results than using minoxidil alone. Using a derma pen is recommended over a roller to avoid scarring.

Chinese researchers have successfully created hair follicles in vitro, potentially offering unlimited hair for transplantation and a cure for hair loss. They plan to test these follicles in vivo on human scalps.

A user shared their 3-month hair growth progress using 1mg oral finasteride, 5% topical minoxidil, and microneedling with a 1.5 mm dermaroller twice weekly. The user received positive feedback and expressed a desire for thicker hair in the future.

Minoxidil is harmful to pets, especially cats, if they contact it. Users recommend switching to oral minoxidil or taking precautions like washing hands and using head coverings to prevent exposure.

The user is using Minoxidil, Finasteride, microneedling, and plans to add low-level laser therapy (LLLT) to treat hair thinning. They shared progress pictures showing results from May 8th to June 7th.

A person is experimenting with microneedling on one temple while using Minoxidil to address hair loss. They plan to needle weekly and apply Minoxidil twice daily, avoiding application around needling sessions.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

Microneedling can still be beneficial when using oral finasteride and minoxidil, with a recommended needle length of 0.5mm to 1.0mm. A stamp or pen is preferred over a roller for microneedling.

The user has been using finasteride for 16 months, minoxidil for 11 months, and started microneedling 2 months ago, experiencing shedding phases. They are questioning whether they are experiencing miniaturization or regrowth.

After 12 months on an oral compound of finasteride, minoxidil, and biotin, the user experienced a seasonal shed and noticed thinner hairs at the hairline, raising concerns about ongoing miniaturization. Another user shared a similar experience and mentioned switching to dutasteride after genetic testing showed finasteride was ineffective.

A user discusses the potential of caffeine and DMG in shampoo for treating hair loss, citing a pending patent and personal plans to test it. They find it more convenient than using minoxidil, tretinoin, and microneedling.

The user shared their 3-month progress using 5% topical minoxidil and microneedling with a 1mm dermaroller, noting significant hair growth without using finasteride. They applied minoxidil twice daily and used the dermaroller three times a week, experiencing a short shedding phase after 2-3 weeks.

The user is experiencing a minoxidil shed after six months of use, noting a significant number of miniaturized hairs compared to mature ones, and has been on finasteride 0.5mg daily for two years with positive results. The user meticulously counts and categorizes shed hairs, sparking reactions ranging from amusement to concern over the level of obsession.

Minoxidil and microneedling were used for hair loss treatment over 49 days. The user is advised to be patient and avoid overanalyzing results.

The conversation discusses hair loss treatments, specifically using Minoxidil, microneedling, and finasteride. The user is concerned about worsening hair loss and is advised to consider finasteride.

A trans woman experiencing male pattern baldness has been using Minoxidil and microneedling for 3.5 months, noticing visible hair regrowth. Despite initial skepticism, progress is evident, though a hair transplant might be needed for fuller coverage.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

The user is updating on their 3-month progress using minoxidil (0.5mg twice daily) and microneedling once a week. They plan to consult a doctor about adding finasteride to their regimen.

The user experienced hair regrowth using finasteride for 2 years, minoxidil for 2 months, and microneedling once a month. They reported no side effects and used 5% topical minoxidil in liquid form.